Shattuck Labs, Inc. Proceeds from Stock Options Exercised
Shattuck Labs, Inc. (STTK) reported Proceeds from Stock Options Exercised of $1.29 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-12.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2021-08-12
- Shattuck Labs, Inc. proceeds from stock options exercised for the quarter ending 2021-06-30 was $1.26M.
- Shattuck Labs, Inc. proceeds from stock options exercised for the quarter ending 2021-03-31 was $31.00K, a 416.67% increase year-over-year.
- Shattuck Labs, Inc. proceeds from stock options exercised for the quarter ending 2020-12-31 was $15.00K.
- Shattuck Labs, Inc. proceeds from stock options exercised for the quarter ending 2020-09-30 was $214.00K.
- Shattuck Labs, Inc. proceeds from stock options exercised for fiscal 2020 was $229.00K.
- Shattuck Labs, Inc. proceeds from stock options exercised for fiscal 2019 was $0.00.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2021-06-30 | $1.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.29M 10-Q · filed 2021-08-12 | $1.30M derived: sum of 3 quarters · filed 2021-08-12 | $1.52M derived: sum of 4 quarters · filed 2021-08-12 |
| 2021-03-31 | $31.00K 10-Q · filed 2021-05-10 | $46.00K derived: sum of 2 quarters · filed 2021-05-10 | $260.00K derived: sum of 3 quarters · filed 2021-05-10 | $254.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $229.00K derived: sum of 2 quarters · filed 2021-03-16 | $223.00K derived: sum of 3 quarters · filed 2021-08-12 | $229.00K 10-K · filed 2021-03-16 |
| 2020-09-30 | $214.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $208.00K derived: sum of 2 quarters · filed 2021-08-12 | $214.00K 10-Q · filed 2020-11-13 | $214.00K derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-06-30 | -$6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2021-08-12 | |
| 2020-03-31 | $6.00K 10-Q · filed 2021-05-10 | $6.00K derived: sum of 2 quarters · filed 2021-05-10 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 10-K · filed 2021-03-16 | ||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |